T cells are the immune system’s frontline fighters. When they detect danger, they rapidly multiply and transform into ...

Genrix’s velinotamig complements Cullinan’s own pipeline, according to William Blair, which added that the deal will put ...

The deal gives Cullinan T cell engagers aimed at BCMA and CD19, which drugmakers are exploring as possible targets for ...

How CD4+ T cells respond to Chikungunya virus may trigger long-lasting joint pain, mimicking autoimmune disease long after ...

The brain is a unique place. It is shielded from much of the body by the blood-brain barrier, meaning it's protected from ...

Cell and gene therapies harbor great hopes for biomedicine. They are becoming increasingly important for diseases that are ...

Cullinan Therapeutics has announced a licensing agreement with Genrix Bio for global rights to velinotamig, a clinical-stage ...

Celiac disease frustratingly restrictive, the only real medical intervention for sufferers being to avoid gluten altogether.

The dual-targeting CAR T-cell therapy KITE-363 showed positive response rates and manageable side effects in relapsed or ...

An autoantibody associated with systemic lupus erythematosus may help improve the performance of immune checkpoint inhibitor ...

Findings indicate that frequent COVID-19 booster shots do not weaken T-cell responses, alleviating concerns for vulnerable ...